First Time Loading...

I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 1.76 USD -0.28% Market Closed
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

IMAB Price Targets Summary
I-Mab

There are no price targets for IMAB.
IMAB Lowest Forecast
Wall Street Target
Not Available
IMAB Average Forecast
Wall Street Target
Not Available
IMAB Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
I-Mab Competitors:
Price Targets
ICCC
ImmuCell Corp
178% Upside
VCYT
Veracyte Inc
55% Upside
4142
Adimmune Corp
27% Upside
1801
Innovent Biologics Inc
37% Upside
ICCC
ImmuCell Corp
178% Upside
VCYT
Veracyte Inc
55% Upside
4142
Adimmune Corp
27% Upside
1801
Innovent Biologics Inc
37% Upside
TGTX
TG Therapeutics Inc
92% Upside
B
BAVA
Bavarian Nordic A/S
77% Upside
EXEL
Exelixis Inc
25% Upside
TRDA
Entrada Therapeutics Inc
63% Upside

Revenue
Forecast

Revenue Estimate
I-Mab

For the last 5 years the compound annual growth rate for I-Mab's revenue is -12%. The projected CAGR for the next 3 years is 281%.

-12%
Past Growth
281%
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
I-Mab

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
I-Mab

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
IMAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
IMAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IMAB stock valuation using valuation multiples.
Wall Street Estimates
IMAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IMAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IMAB's stock price target?
Not Available

IMAB doesn't have any price targets made by Wall Street professionals.

What is I-Mab's Revenue forecast?
Projected CAGR
281%

For the last 5 years the compound annual growth rate for I-Mab's revenue is -12%. The projected CAGR for the next 3 years is 281%.

ALPHA SPREAD
Join more than 134,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.